About Kaleido
Kaleido is a company based in Utrecht (Netherlands) founded in 2013 by Tim Oakes. It operates as a HealthTech, and Direct-to-Consumer (D2C). Kaleido has raised $183.29 million across 5 funding rounds from investors including EQT, Kreos Capital and Life Sciences Partners. Kaleido offers products and services including Kaleido Insulin Pump and DBLG1 Hybrid Closed Loop System. Kaleido operates in a competitive market with competitors including Tandem Diabetes, Modular Medical, LenoMed, Asante Solutions and Sooil Development, among others.
- Headquarter Utrecht, Netherlands
- Founders Tim Oakes
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Vicentra B.V.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$183.29 M (USD)
in 5 rounds
-
Latest Funding Round
$13 M (USD), Series D
Jan 08, 2026
-
Investors
EQT
& 12 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Kaleido
Kaleido offers a comprehensive portfolio of products and services, including Kaleido Insulin Pump and DBLG1 Hybrid Closed Loop System. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Insulin pump designed for flexible diabetes management daily.
System integrated for automated insulin delivery control.
Unlock access to complete
Funding Insights of Kaleido
Kaleido has successfully raised a total of $183.29M across 5 strategic funding rounds. The most recent funding activity was a Series D round of $13 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series D — $13.0M
- First Round First Round
- Investors Count 13
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2026 | Amount | Series D - Kaleido | Valuation |
investors |
|
| Sep, 2025 | Amount | Series D - Kaleido | Valuation | Innovation Industries | |
| Dec, 2021 | Amount | Series C - Kaleido | Valuation | Partners in Equity |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Kaleido
Kaleido has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include EQT, Kreos Capital and Life Sciences Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Partners in Equity is focused on impact investments for environmental solutions.
|
Founded Year | Domain | Location | |
|
Private equity investments in life sciences businesses are managed.
|
Founded Year | Domain | Location | |
|
AI, deeptech, and healthcare tech companies are funded by Inkef.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Kaleido
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Kaleido
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Kaleido Comparisons
Competitors of Kaleido
Kaleido operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tandem Diabetes, Modular Medical, LenoMed, Asante Solutions and Sooil Development, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of devices for continuous glucose monitoring and manual insulin delivery
|
|
| domain | founded_year | HQ Location |
Insulin pumps are developed for continuous delivery to diabetic patients.
|
|
| domain | founded_year | HQ Location |
Developer of closed loop insulin delivery devices
|
|
| domain | founded_year | HQ Location |
Insulin pump systems are developed and customized by Asante Solutions.
|
|
| domain | founded_year | HQ Location |
Develops insulin pumps and apps for diabetes care and blood sugar monitoring.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Kaleido
Frequently Asked Questions about Kaleido
When was Kaleido founded?
Kaleido was founded in 2013 and raised its 1st funding round 3 years after it was founded.
Where is Kaleido located?
Kaleido is headquartered in Utrecht, Netherlands.
Who is the current CEO of Kaleido?
Thomas Arnold is the current CEO of Kaleido.
Is Kaleido a funded company?
Kaleido is a funded company, having raised a total of $183.29M across 5 funding rounds to date. The company's 1st funding round was a Series C of $74M, raised on Jan 20, 2016.
What does Kaleido do?
Kaleido, operated by ViCentra B.V., is dedicated to providing advanced diabetes management solutions through its innovative insulin pump technology. The company offers the Kaleido Insulin Pump, designed for flexibility with customizable wear options and integrated with the DBLG1 Hybrid Closed Loop system for automated insulin delivery. Serving the healthcare sector, particularly in diabetes care, Kaleido emphasizes user freedom and personalized care with features like self-learning algorithms and 247 data insights. Its solutions are currently available in the Netherlands and Germany, targeting adults with type 1 diabetes.
Who are the top competitors of Kaleido?
Kaleido's top competitors include Tandem Diabetes, Modular Medical and LenoMed.
What products or services does Kaleido offer?
Kaleido offers Kaleido Insulin Pump and DBLG1 Hybrid Closed Loop System.
Who are Kaleido's investors?
Kaleido has 13 investors. Key investors include EQT, Kreos Capital, Life Sciences Partners, Partners in Equity, and Direct Recruiters.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.